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ZNF687 Mutations in Severe Paget Disease of Bone
Associated with Giant Cell Tumor
Giuseppina Divisato,1 Daniela Formicola,1 Teresa Esposito,1 Daniela Merlotti,2 Laura Pazzaglia,3
Andrea Del Fattore,4 Ethel Siris,5 Philippe Orcel,6 Jacques P. Brown,7 Ranuccio Nuti,2
Pasquale Strazzullo,8 Maria Serena Benassi,3 M. Leonor Cancela,9 Laetitia Michou,7
Domenico Rendina,8,10 Luigi Gennari,2,10 and Fernando Gianfrancesco1,10,*
Paget disease of bone (PDB) is a skeletal disorder characterized by focal abnormalities of bone remodeling, which result in enlarged and
deformed bones in one or more regions of the skeleton. In some cases, the pagetic tissue undergoes neoplastic transformation, resulting
in osteosarcoma and, less frequently, in giant cell tumor of bone (GCT).We performedwhole-exome sequencing in a large family with 14
PDB-affected members, four of whom developed GCT at multiple pagetic skeletal sites, and we identified the c.2810C>G (p.Pro937Arg)
missensemutation in the zinc finger protein 687 gene (ZNF687). Themutation precisely co-segregated with the clinical phenotype in all
affected family members. The sequencing of seven unrelated individuals with GCT associated with PDB (GCT/PDB) identified the same
mutation in all individuals, unravelling a founder effect. ZNF687 is highly expressed during osteoclastogenesis and osteoblastogenesis
and is dramatically upregulated in the tumor tissue of individuals with GCT/PDB. Interestingly, our preliminary findings showed that
ZNF687, indicated as a target gene of the NFkB transcription factor by ChIP-seq analysis, is also upregulated in the peripheral blood of
PDB-affected individuals with (n¼ 5) or without (n¼ 6)mutations in SQSTM1, encouraging additional studies to investigate its potential
role as a biomarker of PDB risk.Introduction
Paget disease of bone (PDB [MIM: 602080]) is a common
metabolic bone disorder characterized by focal areas of
increased osteoclastic bone resorption coupled with a
disorganized increase in osteoblastic bone formation.1–3
These abnormalities disrupt normal bone architecture
and result in enlarged and deformed bones in one (mono-
stotic form) or more (polyostotic form) regions of the skel-
eton. In less than 1% of cases, pagetic tissuemight undergo
neoplastic transformation, resulting in osteosarcoma and,
less frequently, in giant cell tumor of bone (GCT); only
117 cases of GCT associated with PDB (GCT/PDB) are re-
ported in the literature.4–7 These tumors arise in bones
affected by PDB, and can appear as multifocal lesions.
Despite the fact that familial clustering has been described
in PDB-affected individuals with GCT, the underlying ge-
netic alterations and the molecular basis of tumorigenesis
in pagetic tissue remain to be defined.
Genetic factors are important in the pathogenesis of
PDB, and in many affected families, inheritance has been
described as autosomal dominant. Since 2002, mutations
in SQSTM1 (MIM: 601530) have been identified in up to
40% and 10% of individuals with familial and sporadic
PDB, respectively.8,9 Genome-wide association studies
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The Americuals with PDB who are negative for SQSTM1 muta-
tions.10,11 Recently, we reported on a large family with
14 members affected by PDB, four of whom developed
GCT at single or multiple pagetic skeletal sites.12 We
excluded the presence of mutations in SQSTM1 or in other
genes known to be associated with PDB-related syndromes
(TNFRSF11A [MIM: 603499], TNFRSF11B [MIM: 602643],
VCP [MIM: 601023], and identified multiple chromosomal
regions, potentially housing the causative mutation.12,13
We now report the identification of a heterozygous
missense mutation in ZNF687 (MIM: 6010568) in all
affectedmembers of the family and in seven additional un-
related individuals with GCT/PDB. The same mutation
(c.2810C>G) and one additional mutation (c.725G>T) in
ZNF687 (GenBank: NM_020832.2) were also detected in
two families and in some severe PDB cases (with earlier
onset and an increased number of affected skeletal sites)
from two cohorts of pagetic individuals with different ge-
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Figure 1. Identification of the c.2810C>G Mutation in ZNF687
(A) The pedigree of family 1, including 14 affected members, four of whom developed GCT at pagetic skeletal sites. Circles indicate fe-
male family members, and squares indicate male family members; slashes indicate that the family member is deceased. Family members
with the GCT/PDB phenotype are indicated by a white dot in solid symbols, those with PDB are indicated by solid symbols, and those
without any clinical symptoms are indicated by open symbols.þ or – signs indicate the presence or absence of the c.2810C>Gmutation.
This panel also includes the pedigree for a different family (family 2) with the same c.2810C>G mutation in ZNF687. The index indi-
vidual with PDB (II-1) is indicated by an arrow.
(B) The DNA sequence of a segment flanking c.2810C>G in ZNF687 from an unaffected family member (left) and a heterozygous GCT/
PDB-affected individual (right). A single base substitution changes the non-mutant cytosine to guanine, leading to the substitution of
proline (P) for arginine (R) at the 937 codon (indicated by a solid line).
(C) A portion of the amino acid sequence of ZNF687 from diverse mammal species.
(D) The ancestral haplotype with rare variants in SV2A-rs149735232 (t minor-allele frequency ¼ 1.5%), SETDB1-rs138864506 (t minor-
allele frequency¼ 0.1%), ZNF687-rs142842127 (aminor-allele frequency¼ 0.2%), andHRNR (ta deletion, frequency not available), all of
which are genes surrounding the c.2810C>G mutation in ZNF687. For each variant, the position on chromosome 1 is indicated by
arabic numerals.provided in Figure 1A, Table 1, and Table S1. A replication
cohort of seven unrelated PDB individuals with a history of
GCT degeneration was also included in the study (Table 1).
Moreover, 30 additional families affected by PDB, 20 of which
were negative for mutation screening of SQSTM1 or other genes
associated with PDB-related syndromes, were also tested for
ZNF687 mutations. Then, we extended the screening of
ZNF687 mutations to two separate cohorts of PDB-affected indi-
viduals of Italian (n ¼ 628) and multiethnic American (n ¼
342) backgrounds; these cohorts were previously analyzed for
SQSTM1 mutations. Unaffected control individuals of Italian
(n ¼ 564) and North-American (n ¼ 269) origins were also
screened as a reference. Clinical characteristics of PDB-affected
individuals and control individuals are shown in the Supple-276 The American Journal of Human Genetics 98, 275–286, Februarymental Data (Table S2). The studies were approved by ethics re-
view committees at the relevant institutions and all participants
provided informed consent.
Whole-Exome Sequencing Strategy
Genomic DNA samples from four family members belonging to
the extended pedigree were tested with the NimbleGen SeqCap
EZ ExomeTM capture kits (Roche), and the resultant fragments
were sequenced on an Illumina GAIIx (Illumina) with 90 bp
paired-end reads. Reads were obtained and aligned to the human
reference genomic sequence (UCSC Genome Browser GRCh37/
hg19) with MAQ7 and NextGENe software v.2.0. We adopted a
prioritization scheme, described in Table S3, to identify the path-
ogenic mutation in each individual, similar to the approach4, 2016
Table 1. Clinical Characteristics of Subjects with Familial and Sporadic PDB and Positive for ZNF687 Mutations
Patient ZNF687 Mutation Sex Origin GCT
PDB Onset
(Age in Years) No. of PDB sites CHD
Family 1
1.V-4 c.2810C>G M Italian yes 35 12 yes
1.V-18 c.2810C>G M Italian no 41 5 yes
1.V-11 c.2810C>G M Italian yes 41 6 yes
Family 2
2.II-1 c.2810C>G M Italian no 45 4 yes
2.II-3 c.2810C>G F Italian no 26 10 no
Family 3
3.II-1 c.725G>T M Italian no 50 4 yes
3.II-2 c.725G>T F Italian no 59 2 yes
3.II-3 c.725G>T F Italian no 43 3 yes
Unrelated Individuals with GCT/PDB
GCT/PDB1 c.2810C>G M Italian yes 33 7 yes
GCT/PDB2 c.2810C>G F Italian-American yes NA 2 NA
GCT/PDB3a c.2810C>G F Italian-American no NA 2 NA
GCT/PDB4b c.2810C>G F Italian-American yes NA 8 NA
GCT/PDB5 c.2810C>G M Italian yes 38 7 yes
GCT/PDB6 c.2810C>G M Italian yes 53 5 NA
GCT/PDB7 c.2810C>G M Italian yes 46 5 NA
Unrelated Individuals with PDB
PDB1 c.2810C>G M Italian no 37 5 yes
PDB2 c.2810C>G M Italian no 39 10 yes
PDB3 c.2810C>G F Italian no 53 7 yes
PDB4 c.2810C>G F French-Canadian no 61 2 NA
PDB5 c.2810C>G F French-Canadian no 59 1 NA
M, female; F, female; PDB, Paget disease of bone; GCT, giant cell tumor of bone; CHD, coronary heart disease; NA, data not available.
aMother and three siblings had PDB, mother also had GCT.
bMother with PDB had either GCT or osteosarcoma.used in our recent study.16 First, in order to reduce the number of
candidate variants, we excluded the variants registered in the
dbSNP131 and in our four in-house exomes, derived from four in-
dividuals with unrelated diseases and whose genetic basis was
identified in our previous studies.16,17 After filtering, we compared
data from three affected individuals (V-4, V-18, andV-11) to obtain
shared variants, and we excluded those present in the healthy sub-
ject (V-7), thus identifying 57 variations in 45 genes (Table S4).
Sanger sequencing allowed us to validate 21 out of these 57
variations.
Mutation Analysis of ZNF687
We conducted mutation screening of all 9 exons of ZNF687 and
their intron-exon boundaries by using PCR followed by automated
DNA sequencing. PCR reactions (25 mL) were performed with TaqThe AmericDNA polymerase (1 U; Fermentas), 13 buffer, deoxynucleoside
triphosphate (dNTP, 0.2 mM; Amersham), primers (0.5 mM), and
DNA (100 ng). PCR conditions were as follows: initial denatur-
ation at 94C for 3 min, followed by 35 cycles of 94C for 30 s,
30 s at annealing temperature, extension at 72C for 45 s, and a
final extension for 10 min at 72C.
Samples were ExoSap-digested (Amersham) and sequenced
with the Big Dye Terminator Ready Reaction Kit (Applied Bio-
systems). Sequencing reactions were performed with a 9700
Thermal Cycler (Applied Biosystems) for 25 cycles of 95C for
10 s, 50C for 5 s, and 60C for 2 min. After sequencing, each re-
action was column purified (Amersham) to remove excess dye
terminators.
The sequencing of the products was performed with the ABI
Prism 3710 Genetic Analyzer (Applied Biosystems).an Journal of Human Genetics 98, 275–286, February 4, 2016 277
Primers used for ZNF687 amplification and sequencing are re-
ported in Table S5.
ZNF687 Tissue Expression Pattern
The tissue expression pattern of ZNF687 was determined by real-
time PCR (Figure S3) with the Light-Cycler system DNA Engine
Opticon 2 (Biorad) and was performed on total RNAs derived
from human adult tissues that were purchased from Stratagene.
Total RNAwas reverse transcribed with a RevertAid RT kit (Thermo
Scientific). qPCRs were performed with SYBR Select Master Mix for
CFX (Applied Biosystems) on a Bio-Rad CFX Connect Real-Time
System instrument. The ZNF687 transcript primers used to eval-
uate ZNF687 mRNA expression are reported in Table S5. HPRT
primers were used to normalize ZNF687 expression (Table S5).
This experiment was carried out in triplicate.Generation of Human Osteoclasts from PBMCs
Osteoclasts were generated in vitro, with peripheral blood mono-
nuclear cells (PBMCs) from healthy volunteers and age- and sex-
matched pagetic individuals. PBMCs were isolated from citrate
blood samples by density-gradient centrifugation in Ficoll (Histo-
paque 1077 Human Lymphocyte, Sigma-Aldrich), washed in 13
PBS, and re-suspended in alpha-minimal essential medium
(a-MEM) (Sigma-Aldrich, Life Science), containing 100 U/mL
penicillin, 100 mg/mL streptomycin (Gibco), 2 mM L-glutamine
(Life Technologies) and 10% heat-inactivated fetal bovine serum
(FBS). PBMCs were cultured in 96-well plates (8 3 105 cells per
well) for RNA extraction, tartrate resistant acid phosphatase
(TRAP) staining, and immunofluorescence. The cells were cultured
in a humid atmosphere with 5% CO2 in a-MEM and, after over-
night incubation, the cultures were supplemented with
20 ng/mL of macrophage colony-stimulating factor (M-CSF; Pe-
proTech) and 30 ng/mL of soluble human recombinant RANK
ligand (sRANKL; PeproTech) and cultured for 14 days. Total RNA
extractionwas performed with TRIzol Reagent (Sigma-Aldrich), ac-
cording to the manufacturer’s protocol. Total RNA reverse tran-
scription and qPCR were performed as described above. ZNF687
expression profile during in vitro human osteoclastogenesis was
obtained with the primers reported in Table S5.
At the end of the culture, cells were fixed for 20 min at room
temperature with 4% paraformaldehyde (Sigma-Aldrich) and
stained for TRAP activity with a 87A Sigma Acid Phosphatase,
Leukocyte (TRAP) Kit (Sigma-Aldrich). The nuclei were counter-
stained with methyl green. Multinucleated TRAP-positive cells
were considered to be differentiated osteoclasts and were counted
under a Zeiss microscope. For immunofluorescence assay, the
TRAPþ cells were washed several times in 13 PBS and then incu-
bated with 0.1% Triton X-100 (EuroClone) for 10 min at 4C.
Then, the cells were washed several times with 13 PBS and incu-
bated with Texas RedsX-phalloidin (Life Technologies) for
20 min. The nuclei were counterstained with DAPI. Slides were
analyzed with a Zeiss Axioplan.Generation of Human Osteoblasts from Molar
Follicles
Normal human third-molar follicles were collected from tooth
buds of healthy pediatric individuals, aged 8–12 years andwho un-
derwent extractions for orthodontics reasons, after obtaining
informed consent from the parents of each individual. Dental fol-
licles (DFs) were digested for 1 hr at 37C in agitation in a solution
of 3 mg/mL type I collagenase plus 4 mg/mL dispase (Gibco).278 The American Journal of Human Genetics 98, 275–286, FebruarySingle-cell suspensions were obtained by passing the cells through
a 70 mmBDFalcon strainer (BectonDickinson). After filtration, sin-
gle cell suspensions were seeded in a 25 cm2 culture flask and
cultured in a-MEM supplemented with 5% FBS, 100 U/mL peni-
cillin-G, 100 mg/mL streptomycin, and 0.25 mg/mL fungizone
(Gibco). Flasks were incubated at 37C and 5%CO2. For the induc-
tion of osteoblastic differentiation, the cells were grown in a-MEM
supplemented with 2% FBS, 108 M dexamethasone, and
50 mg/mL ascorbic acid (Sigma-Aldrich). For in vitro mineralized
nodule evaluation, we cultured them for 30 days in a-MEM, sup-
plemented with 10 mM b -glycerophosphate (Sigma-Aldrich).
Total RNA extraction was performed with TRIzol Reagent (Sigma-
Aldrich), according to the manufacturer’s protocol. One mg of total
RNA was reverse transcribed as previously described. qPCRs were
performed as previously described. ZNF687 expression profile dur-
ing in vitro human osteoblastogenesis was obtained with the
primers reported in Table S5.Ethics Statement
Animal handling and experiments were legally accredited by the
Portuguese Direcc¸a˜o Geral de Veterina´ria, and all the experimental
procedures involving animals were performed according to the EU
(Directive 86/609/CEE) andNational (Portaria n 1005/92 de 23 de
Outubro; Portaria n 466/95 de 17 de Maio; Portaria n 1131/97 de
7 de Novembro) legislation for animal experimentation and
welfare.Fish Maintenance
Zebrafish eggs were obtained from natural spawning of in-house
broodstock maintained in a ZebTec housing system (Tecniplast).
Water parameters were maintained as follows: pH 7.65 0.2, con-
ductivity 700 mS, dissolved oxygen 7.8 mg/L, and photoperiod
14:10 hr light:dark. Fertilized eggs were maintained until hatch-
ing in 1 L water tanks at a density of 200 eggs/L and with
0.5 ppm of methylene blue to avoid fungi development. Hatched
larvae were raised until 30 days post-fertilization (dpf) in 1 L water
tanks at a density of 100 larvae/L, and 90% of the water was re-
newed every 2 days. Larvae from 5 to 10 dpf were fed twice a
day with Artemia nauplii (AF strain INVE, 5–10 nauplii/mL) and
from 8 to 30 dpf with Artemia metanauplii (EG strain INVE,
10 metanauplii/mL). Juveniles, adults, and broodstock were main-
tained in 10 L plastic tanks with recirculating fresh water at 28C
(Tecniplast ZebTEC) and fed twice a day with commercial
dry food (Tetramin flake C) and once a day with Artemia
metanauplii.Larval and Tissue Sampling
Fish embryos and larvae were sampled at 1 (4 cells), 3 (1,000–
2,000 cells), 16 (14 somites), 24, 32, 48, 72, and 96 hr post-fertil-
ization (hpf), and 5, 7, 9, 15, 20, and 30 dpf. The amount of
material sampled at each developmental stage was adapted to
specimen size and included about 100 eggs for the earliest
developmental stages and five Danio rerio specimens for early ju-
veniles (30 dpf). Adult zebrafish tissues (eye, operculum, vertebra,
gills, liver, kidney, spleen, ovary, and scales) were collected and
pooled from three males and two females. All fish were anesthe-
tized with a lethal dose of tricaine methanesulfonate (MS-222;
Sigma-Aldrich) and washed with sterile distilled water before
sampling. For fin and blastema recovery, 20 adult fish were
anesthetized, as mentioned above, and washed with PBS. Fins
were then amputated, washed in PBS, and pooled to obtain4, 2016
two biological replicates. 36 hr post-amputation (hpa), fish were
re-anesthetized and the blastemas were recovered, washed with
PBS, and pooled to obtain two biological replicates.
Specimens and tissues collected for gene-expression analysis
were placed in ten volumes of TRI Reagent (Ambion) and stored
at 80C until processed.
Danio rerio RNA Extraction and qPCR
Total RNA was extracted from samples stored in TRI-Reagent, ac-
cording to the manufacturer’s instructions, and purified with a
High Pure RNA Isolation Kit (Roche). RNA integrity was confirmed
with an Experion Automated Electrophoresis System (Bio-Rad).
Total RNA was reverse transcribed with M-MLV reverse transcrip-
tase (Invitrogen), according to the manufacturer’s protocol.
qPCR was performed in triplicate with isoform-specific primers
(Table S5). Levels of gene expression were calculated with the
DDCt comparative method and normalized with housekeeping
rps18 (Table S5).
Bioinformatic Predictions
The NLStradamus program was used to predict the nuclear locali-
zation site of ZNF687.18,19 The NetPhos 2.0 server was used to pre-
dict serine, threonine, and tyrosine phosphorylation sites in
ZNF687.20
Immortalization and Cell Culture of Lymphoblasts
10 mL of blood were drawn from a peripheral vein, and lympho-
blasts were isolated on a Ficoll-Diatrizoate density gradient (Fi-
coll-Paque; Pharmacia). B-lymphoblasts were immortalized by
incubation with supernatant containing Epstein-Barr virus. After
immortalization, B-lymphoblasts were grown for 10–14 days in
RPMI 1640 medium (Gibco), supplemented with 2 mM L-gluta-
mine, 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco),
and 20% FBS.
Cytoplasmic and Nuclear Protein Extraction from
Lymphoblasts
The cells were washed with cold PBS (2.7 mM KCl, 1.2 mM
KH2PO4, 8.1 mM Na2HPO4, 138 mM NaCl [pH 7.4]) and cyto-
plasmic extraction was obtained in 100–1,000 mL of hypotonic
buffer (10 mM Tris-HCl [pH 7.5], 2mM MgCl2, 10 mM CaCl2,
30 mM Sucrose, 1% NP40) and 13 proteinase inhibitor mixture
(20 mg of 4-amidinophenyl-methanesulfonyl fluoride, 25 mg of
antipain, 20 mg of aprotinin, 5 mg of nitobestatin, 20 mg of chymos-
tatin, 25 mg of 3,4-dichloroisocoumarin, 50 mg of E-64, 10 mg of leu-
peptin, 10 mg of pepstatin A and 10 mg of phosphoramidon permL,
50 mM bezamidine, 50 mM sodium metabisulfite). The lysis was
performed with a syringe with a narrow-gauge (no. 27) hypoder-
mic needle and was observed by the addition of a Trypan Blue
solution. Then, the disrupted cells were centrifuged for 20 min
at 10,000–11,000 rcf (relative centrifugal force). Nuclear extracts
were sequentially obtained in 140 mL of extraction buffer
(0.42MNaCl, 0.2mMEDTA, 25%Glycerol, 1%NP40) and 13 pro-
teinase inhibitor mixture. Crude nuclei were shaken gently and
then incubated for 10min on ice. Finally, nuclear extracts were ob-
tained through centrifugation for 5 min at 20,000–21,000 rcf.
Western Blot Analysis for ZNF687 Cytoplasmic and
Nuclear Localization
Proteins were denatured by being boiled in sample buffer, sepa-
rated on 8% SDS-PAGE, transferred onto a Immun-Blot PVDFThe AmericMembrane For Protein Blotting (Bio-Rad), and blocked for 1 hr
in 5% non-fat powdered milk in TBS-T (10 mM Tris-HCl [pH
7.5], 100 mM, NaCl, 0.1% [v/v] Tween-20). Rabbit polyclonal
anti-ZNF687 antibody ab105544 (1:500 diluted in TBS-T; Abcam),
a Tubulin (B-7) sc-5286 (1:500 diluited in TBS-T; Santa Cruz), and
anti-RNA polymerase II ab815 (1:1,000 diluted in TBS-T; Abcam,)
were used for protein detection. Peroxidase-conjugated goat anti-
rabbit (1:1,000 for ZNF687) and anti-mouse (1:1,000 diluted in
TBS-T for a tubulin and 1:2,000 diluted in TBS-T for RNA polymer-
ase II; Bio-Rad) were used as secondary antibodies. Western blot as-
says were quantified with the ImageJ program.
RNA Extraction from Peripheral Blood of Pagetic
Individuals
Venous blood derived from healthy volunteers and pagetic indi-
viduals (age- and sex-matched) was collected in a Tempus Blood
RNA tube (Applied Biosystems) and immediately incubated at
room temperature for 24 hr. RNA was extracted with a Tempus
Spin RNA Isolation Reagent Kit (Applied Biosystems), and its qual-
ity was determined by a NANOD 1000 v.3.7.1 spectrophotometer
(Thermo Scientific). Total RNA was reverse transcribed with Rever-
tAid RT kit (Thermo Scientific) and qPCR was performed with the
primers reported in Table S5. The experiment was carried out in
triplicate.
GCT Tumor Tissues
The GCT/PDB tissue samples were obtained from surgically
removed tumors, frozen in liquid nitrogen, and stored at 80C.
Total RNAwas extracted from five frozen tumor tissues with TRIzol
Reagent (Sigma-Aldrich), according to the manufacturer’s proto-
col. Total RNA was reverse transcribed as previously mentioned,
and qPCRs were performed in triplicate with the primers reported
in Table S5.
Immunohistochemistry Assay
ZNF687 immunohistochemical analysis was performed on GCT
paraffin-embedded microsections. H&E-stained slides were care-
fully reviewed, and the diagnosis of GCT/PDB was confirmed.
Several sections of GCT/PDB tissue served as control tissue. A
Dako LSAB 2 SystemHRP Kit (Universal Dako Labeled Streptavidin
Biotin 2 System Horseradish Peroxidase) was used on formalin-
fixed, paraffin-embedded material from primary tumors. Sections
(5 mm thick) were deparaffinized in xylene and rehydrated in
graded alcohols and water and the endogenous peroxidase was
blocked by treating the sections with 0.3% H2O2 for 5 min at
room temperature. Microwave pre-treatment was used to reveal
the antigens to reduce nonspecific binding. The sections were
incubated with blocking serum for 15 min, then at 4C overnight
with goat polyclonal anti-ZNF687 antibody (E-20 sc-324734; Santa
Cruz) at the dilution 1:100. The sections were then incubated with
the biotinylated secondary antibody and subsequently with ABC
(avidin-biotin-peroxidase complex; Biomeda). The staining was
developed in DAB (3,30-Diaminobenzidine), and the nuclei were
counterstained with hematoxylin. Positive controls were included
for each antibody and negative controls were prepared without
the incubationwith the primary antibody. The staining was scored
for intensity (0¼ no expression, 1¼weak to moderate expression,
2 ¼ strong expression) by two different investigators and for the
percentage of positive cells (0 % 10%, 1 ¼ 10%–25%, 2 ¼ 26%–
50%, 3 R 50%). Cut-off levels for the sum of scores were applied
as for negative cases: 1–3 for weakly positive and 4–5 foran Journal of Human Genetics 98, 275–286, February 4, 2016 279
moderately to strongly positive, which is considered protein
overproduction.
Results
Identification of ZNF687 Mutations in GCT/PDB
The pedigrees of familial PDB individuals with GCT and
the clinical features of the affected familymembers are pro-
vided in Figure 1A, Table 1, and Table S1. Considering the
high number of meiotic events in this extended pedigree,
which reduces the number of candidate variants, we per-
formed whole-exome sequencing of three affected PDB in-
dividuals (V-4, V-18, and V-11), two of whomhad recurrent
GCT, and one healthy subject (V-7) from family 1. We
adopted a prioritization scheme, described in Table S3, to
identify the pathogenic mutation in each individual,
similar to the approach used in our recent study.16 After
excluding common SNPs and variants registered in the
dbSNP131 and in our four in-house exomes (which are
derived from four individuals with other diseases not
related to bone metabolism, such as focal segmental glo-
merulosclerosis [MIM: 603278] and congenital fiber type
disproportion [MIM: 255310]), we identified 21 candidate
variants (Tables S3 and S4). Only one showed precise co-
segregation with the disease phenotype in the family: the
c.2810C>G heterozygous change in exon six of ZNF687,
which causes the p.Pro937Arg amino acid change
(Figure 1B). ZNF687 is localized on chromosome 1
(1q21.3), in one of the linkage candidate regions described
in our previous report (Figure S1).12
Although its function has been poorly investigated, it is
known that ZNF687, together with ZMYND8 and ZNF592,
is part of the recently described transcriptional regulator
complex Z3.21
The proline residue at the 937 position of ZNF687 is
highly conserved in mammals (Figure 1C). The c.2810C>G
mutation was not identified in a cohort of 564 unrelated
healthy control individuals from the same geographical
origin. Sanger sequencing confirmed the presence of the
same c.2810C>G mutation (founder mutation) in all
affected members of family 1, but not in unaffected mem-
bers. Moreover, the same mutation was detected in seven
additional unrelated individuals with PDB complicated
with GCT (Figure S4). Four of these individuals were
from the same circumscribed area of Southern Italy as fam-
ily 1, and three were North-American individuals of Euro-
pean descent.14,15,22 In order to verify the hypothesis of a
common ancestral chromosome among these GCT/PDB
cases, we analyzed the segregation of rare variants in genes
surrounding the ZNF687 mutation, identifying, in all but
one, identical variants for SV2A (MIM: 185860), SETDB1
(MIM: 604396), ZNF687, and HRNR (MIM: 616293). This
haplotype was not observed in any of the 564 control indi-
viduals of the same ethnic origin, suggesting that the
c.2810C>G mutation originated from a unique haplotype
and segregated in all but one of the GCT/PDB-affected in-
dividuals tested in this study (Figure 1D). The occurrence280 The American Journal of Human Genetics 98, 275–286, Februaryof the c.2810C>G mutation on a different haplotype in
one individual (individual GCT/PDB6) provides the ge-
netic evidence that this mutation is necessary and suffi-
cient for GCT/PDB phenotype development.
Identification of ZNF687 Mutations in Individuals
with Severe PDB
To determine the role of ZNF687 in PDB-affected individ-
uals without neoplastic transformation, we first analyzed
the entire coding region of the gene in 30 additional PDB
probands, 20 of whom were negative for SQSTM1 muta-
tions, as well as for mutations in other genes associated
with PDB-related syndromes. Each of the analyzed pro-
bands had at least another family member with PDB,
showing vertical transmission, which is consistent with
the autosomal-dominant inheritance pattern of the dis-
ease. Mutation analysis identified the c.2810C>G muta-
tion in one proband (II-1, family 2) (Figure 1A) and a
new mutation, c.725G>T (p.Ser242Ile), in exon 2 of
ZNF687 in a different proband (family 3) (Figure 2A). The
c.2810C>G mutation segregated with the disease pheno-
type in family 2; it was detected in the affected relative
(II-3) but not in his healthy brother (II-2). The proband
(II-6) and all affected siblings (II-1 and II-3) of family 3
were heterozygous for the ZNF687 c.725G>T missense
mutation. This mutation was not detected in the three un-
affected family members (II-2, II-4, and II-5) of family 3
(Figures 2A and 2B) and was not reported in the 1000
Genome and ExAC databases. The serine at the 242 posi-
tion of ZNF687 is highly conserved in all species
(Figure 2C), and the p.Ser242Ile change was predicted
in silico (by SIFT, PolyPhen, PMut, and Align GVGD) to
be highly pathogenic, suggesting a causative role. Compu-
tational analysis strongly suggested Ser242 to be an impor-
tant phosphorylation site (score of 0.996 in NetPhos
prediction).20 Subsequently, both the c.2810C>G and
c.725G>T mutations were screened by TaqMan assay in
two cohorts of PDB-affected individuals of different
ethnicity. The c.2810C>G mutation was found in two
out of 615 Italian individuals with PDB and two out of
339 individuals from a multiethnic North-American PDB-
affected cohort. Both mutations were absent in chromo-
some samples from the two cohorts of control individuals
of Italian and North-American origin. All these data sug-
gest that ZNF687mutations are present in a subset of indi-
viduals with familial PDB and more rarely in individuals
with sporadic PDB. Moreover, most individuals with
ZNF687 mutations showed a severe form of PDB, with an
earlier onset and greater number of affected skeletal sites
than individuals with or without SQSTM1 mutations (Ta-
ble 1 and Figure 2D).
Role of ZNF687 in Bone Metabolism
The expression profile of ZNF687 was evidenced by real-
time PCR in all examined adult human tissues, including
bone (Figure S3). To investigate ZNF687mRNA expression
during osteoclast formation, PBMCs from healthy4, 2016
Figure 2. Identification of the c.725G>T Mutation in ZNF687
(A) The pedigree of family 3. The index individual is indicated by an arrow. Individuals with PDB are indicated by black symbols, and
individuals without PDB are shown as unfilled symbols. Circles represent females, squares represent males, and slashes indicate deceased
subjects.
(B) The DNA sequence of a segment flanking c.725G>T in ZNF687 from an unaffected family member (left) and a heterozygous PDB-
affected individual (right). A single base substitution changes the non-mutant guanine to thymine, leading to the substitution of serine
(S) for isoleucine (I) at the 242 codon (indicated by a solid line).
(C) The evolutive conservation of the 242 serine from rodents to humans.
(D) The number of the affected skeletal sites (left) and the age of disease onset (right) across PDB-affected individuals with ZNF687mu-
tations, PDB-affected individuals with SQSTM1 mutations, and PDB-affected individuals without mutations in either gene. Genotype-
phenotype correlations were tested by ANOVA with Bonferroni correction and reported as mean ratio 5 SEM (not mutated, n ¼ 615;
mutated in SQSTM1, n ¼ 78; mutated in ZNF687, n ¼ 20). *p < 0.05; **p < 0.01; ***p < 0.001.volunteers were induced to osteoclastogenesis by treat-
ment with M-CSF and sRANKL. Osteoclastogenesis was as-
sessed by TRAP staining as described in Subjects and
Methods. Our results showed that, after treatment with
M-CSF and RANKL, ZNF687 expression was significantly
increased (Figure 3A). Furthermore, given that GCT derives
from the uncontrolled proliferation of mesenchymal stro-
mal cells committed toward osteoblastic lineage, we also
evaluated ZNF687 expression during osteoblastogenesis.
As expected, ZNF687 mRNA expression was higher in
differentiated osteoblasts than in their undifferentiated
precursors (Figure 3B). Collectively, these data indicate
that ZNF687 plays a role in bone metabolism and that it
is highly expressed during osteoclast and osteoblast differ-The Americentiation. To further verify this, we evaluated the expres-
sion levels of the two zebrafish orthologs (ZNF687a and
ZNF687b) during Danio rerio development and during tis-
sue regeneration (blastema), after caudal fin amputation.
Both genes showed high expression levels during the
regeneration of the caudal fin (Figures 3C and 3D), suggest-
ing a possible role in cell proliferation and differentiation.
Consistent with this observation, both genes appeared to
be maternally inherited and highly expressed in the initial
stages of zebrafish development. Interestingly, expression
of ZNF687a increased again between 24 hr and 5 dpf and
after 20 dpf, when hematopoiesis and osteoclastogenesis
are known to occur in zebrafish (Figure 3E).23 Accordingly,
ZNF687a was also highly expressed in adult kidney andan Journal of Human Genetics 98, 275–286, February 4, 2016 281
Figure 3. Expression and Functional Characterization of ZNF687
(A and B) Expression analysis of ZNF687 during human osteoclastogenesis (A) and human osteoblastogenesis (B). The data shown are
representative of three independent experiments and were analyzed by Student’s t test.
(C and D) The scheme of caudal fin regeneration in zebrafish (Danio rerio) (C) and the expression of ZNF687a and ZNF687b (zebrafish
orthologs) during this process (D).
(E) ZNF687a and ZNF687b expression during Danio rerio development.
(F) Bioinformatic prediction of the NLS in ZNF687 between amino acids 938 and 955 enhanced as a consequence of the substitution of
arginine at the 937 position.
(G) The expression of ZNF687 in nuclear- and cytoplasmic-extracts in lymphoblastic cell lines derived from affected individuals with the
p.Pro937Arg change (PDB-affected individuals 1–4) in comparison to expression in those derived from healthy subjects (control individ-
uals 1 and 2). ZNF687 antibody detected one band of about 135 kDa in the cytoplasm and two bands of about 100 and 135 kDa in the
nucleus. Cytoplasm and nuclear extracts contained only minimal or no contamination (data not shown).
(legend continued on next page)
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spleen tissues, the major organs for proliferation and dif-
ferentiation of the hematopoietic cells, including osteo-
clast precursors (Figure S4).Functional Consequences of ZNF687 Mutation
Bioinformatic analysis suggested that ZNF687 contains a
strong nuclear localization signal (NLS) sequence between
amino acids 938 and 954 (Figure 3F). The substitution of
the arginine at the 937 position generates a stronger NLS
that could enhance ZNF687 nuclear import. Therefore,
we performed cellular protein fractionation analysis fol-
lowed byWestern blotting by using anti-ZNF687 antibody.
Our analysis revealed ZNF687 to be less prominent in the
cytoplasmic fraction in lymphoblastic cell lines derived
from PDB-affected individuals with c.2810C>G mutation
than in those derived from control individuals (Figures
3G and 3H). We also found a parallel increase of ZNF687
in the nuclear fraction, suggesting that c.2810C>G acts
as gain-of-function mutation, altering the nuclear-cyto-
plasmic balance of ZNF687, thus leading to enhanced
availability of this transcription factor in the nucleus. To
directly test the causal link between the c.2810C>Gmuta-
tion in ZNF687 and the osteoclast differentiation process,
human PBMCs, derived from five PDB-affected individuals
carrying the c.2810C>G mutation, were differentiated
into osteoclasts in the presence of sRANKL and M-CSF cy-
tokines. Interestingly, osteoclasts cultured from these indi-
viduals showed a greater number of nuclei (Figures 3I–3J)
as well as a larger surface area (Figures 3I and 3K) than
did those from the control individuals, both features being
peculiar for pagetic osteoclasts.Increased ZNF687 Expression in PDB-Affected
Individuals
Given that PDB is a disease of the osteoclast and ZNF687
is upregulated during osteoclastogenesis, we evaluated
ZNF687 expression in PDB-affected individuals with
different genetic backgrounds. Using real-time PCR, we as-
sessed the expression level of ZNF687 in PBMCs from six
PDB-affected individuals without a SQSTM1 mutation,
five PDB-affected individuals with a SQSTM1 mutation,
five PDB-affected individuals with a ZNF687 mutation,
and three healthy subjects. Of interest, ZNF687 expression
levels were significantly higher in PDB-affected individuals
with (3-fold) or without (2-fold) an SQSTM1mutation than
in the control individuals (Figure 4A and Figure S5). More-
over, a larger increase (5-fold) was observed in PDB-affected
individuals exhibiting the c.2810C>G mutation in
ZNF687 (Figure 4A and Figure S5). These results suggest
that ZNF687 is involved in PDB pathogenesis regardless
of the genetic background of PDB-affected individuals. Its
expression profile remarkably correlates with the clinical(H) The quantifications of cytoplasmic and nuclear fractions.
(I–K) The increased number of nuclei and the increased cellular area
mutation compared to the controls.
*p < 0.05; **p < 0.01; ***p < 0.001.
The Americseverity of the disease. To further clarify ZNF687 involve-
ment in PDB pathogenesis, we first analyzed the ChIPBase
database, an integrated platform for decoding transcrip-
tion factor binding sites (including 11 independent
ChIP-seq experiments of NFkB transcription factor).24
Interestingly, in all experiments, ZNF687 was detected as
a genomic target of NFkB in its putative promoter
(Figure 4B). Similar to ZNF687, ZMYND8 (MIM: 615713)
and ZNF592 (MIM: 613624), the other two partners of
ZNF687 in the Z3 complex formation, are regulated by
NFkB transcription factor, which binds their promoters
(data not shown). Next, we evaluated ZNF687 expression
in tumor tissues derived from five individuals with GCT/
PDB. As expected, in comparison to expression in healthy
bone marrow, a dramatic increase in ZNF687 expression
was observed in the RNAs extracted from tumor biopsies
of these individuals, confirming the pathological role of
ZNF687, whose expression resulted from the c.2810C>G
mutation (Figure 4C). These data were reinforced by
immunohistochemistry assays performed on tumor sec-
tions of the same GCT/PDB-affected individuals, in which
we observed stronger ZNF687 staining in the pathological
giant cells than in the stromal cells, in comparison to the
negative section (Figures 4D and 4E).Discussion
Neoplastic transformation is a rare but serious complica-
tion of PDB, occurring in less than 1% of PDB-affected in-
dividuals. In a recent analysis of the cumulative survival
curves of GCT occurring in individuals with or without
PDB, we demonstrated that about half of PDB-affected in-
dividuals die within five years of the diagnosis of GCT,
increasing to 80% after ten years.7 Here, we identify a
pathogenic missense mutation in ZNF687 (c.2810C>G)
in a large pagetic family characterized by an enhanced
prevalence of GCT in up to 30% of affected members.
The same mutation was also identified in all the tested
unrelated individuals with PDB and GCT, as well as in
one individual with PDB and a positive family history
of GCT. Moreover, replication analysis identified the
ZNF687 c.2810C>G mutation and a new ZNF687 muta-
tion (c.725G>T) in two families with a clear family history
for PDB. A further analysis of two large cohorts of unre-
lated PDB-affected individuals with different ethnic back-
grounds identified the ZNF687 c.2810C>G mutation in
0.3% and 0.6% of cases, respectively. All individuals
harboring mutations, except one, had polyostotic disorder
with a significantly increased number of affected skeletal
sites and an earlier onset of disease than PDB-affected indi-
viduals without the mutation, including PDB-affected in-
dividuals with the SQSTM1 mutation. Taken together,of osteoclasts derived from PDB subjects carrying the c.2810C>G
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Figure 4. Upregulation of ZNF687 in Pe-
ripheral Blood of PDB-Affected Subjects
and in Tumor Tissues of GCT/PDB-
Affected Individuals
(A) The expression of ZNF687 in peripheral
blood from healthy subjects, PDB-affected
individuals without SQSTM1 or ZNF687
mutations, PDB-affected individuals with
an SQSTM1mutation, and PDB-affected in-
dividuals with a ZNF687mutation. * ¼ p <
0.05; ** ¼ p < 0.01; *** ¼ p < 0.001.
(B) NFkB binding sites on the ZNF687 pro-
moter region.
(C) The expression profile of ZNF687 in
frozen tumor tissues from five GCT/PDB-
affected individuals in comparison to the
expression in tissue from healthy bone
marrow.
(D and E) ZNF687 expression on a tumor bi-
opsy of a GCT/PDB-affected individual (D)
in comparison to the tumor section derived
from the same individual (E) without pri-
mary antibody (negative control).
(F)AhypotheticalmodelofZNF687 involve-
ment in the PDB molecular pathway.these results indicate that mutations in ZNF687 are associ-
ated with severe PDB, with a prevalence of 3/31 (10%) in
our familial cases with a documented autosomal-domi-
nant pattern of inheritance, whereas they occur rarely in
non-familial disease. Given that all the individuals with
PDB and GCT tested in this study were positive for themu-
tation, we conclude that this ZNF687 mutation is respon-
sible for severe PDB, sometimes complicated by GCT, in
the presence of an impaired response to antiresorptive
treatment.12
ZNF687 encodes a C2H2 zinc finger protein expressed in
most tissues, including bone, that, together with ZMYND8
and ZNF592, is part of the transcriptional regulator com-
plex Z3.21 Despite different C2H2 zinc finger proteins
being identified as important regulators of skeletal devel-
opment and maintenance, the role of ZNF687 in bone
metabolism has never been identified.25 Our in vitro and
in vivo findings indicate that ZNF687 has bone regulatory
properties. First, it is upregulated during osteoclast and
osteoblast differentiation and is highly expressed during
the regeneration of caudal fins in zebrafish, suggesting a
role of this transcriptional co-regulator in bone cell prolif-284 The American Journal of Human Genetics 98, 275–286, February 4, 2016eration and differentiation. Moreover,
ZNF687 has been shown to be overex-
pressed in all the tested PBMC sam-
ples derived from PDB-affected indi-
viduals, irrespective of the genetic
defect, given that this gene is a down-
stream target of NFkB, allowing us to
hypothesize the mechanism reported
in Figure 4F.
The exact mechanism by which
ZNF687 mutations cause PDB and
eventually GCT remains unknown.
Because a stronger NLS was observed in the presence of
the proline to arginine substitution at the 937 position,
we hypothesize that the mutation acts as a gain of func-
tion, leading to the constitutive accumulation of ZNF687
in the nucleus, thus increasing the transcription of its
downstream targets, which in turn might promote the
development of the disorder. Remarkably, osteoclasts
derived from PBMCs of PDB-affected individuals with the
c.2810C>G mutation in ZNF687 were increased in size
and containedmore nuclei than normal osteoclasts, which
are both features of osteoclasts isolated from pagetic tis-
sue.1–3 These data suggest that the c.2810C>G mutation
might contribute to PDB susceptibility by affecting osteo-
clast phenotype.
In addition, considering that we identified the
c.725G>T mutation in familial individuals only affected
by PDB, we hypothesized that c.725G>T mutation is
responsible for the onset of PDB, but not associated with
GCT development. Therefore, we speculated that, differ-
ently from the c.2810C>G mutation, the biological defect
of c.725G>T does not result in the neoplastic transforma-
tion of PDB tissue. Further functional studies are required
to address this point as well as the biological difference
with the c.2810C>G mutation.
In conclusion, in this study we identified mutations in
ZNF687 as a monogenic cause of a severe, early-onset
form of PDB, which is associated in some instances
(c.2810C>G mutation) with an increased likelihood of
GCT. This evidence, together with our in vitro and in vivo
experimental observations, emphasizes a previously unex-
pected role of ZNF687 in bone metabolism. It would be of
interest to determine the ZNF687 role in other neoplastic
conditions related to PDB, such as osteosarcoma, that,
like GCT, are due to the malignant transformation of
mesenchymal stromal cells.
Finally, a better characterization of the downstream
pathways regulated by this transcriptional co-regulator in
bone cells might be relevant for the identification of new
therapeutic targets for PDB and other disorders of skeletal
metabolism.Supplemental Data
Supplemental Data include five figures and five tables and can be
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